Century Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
IPSC$1.81+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Item No. · PageNo. | ||
|---|---|---|
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS | 3 | |
| PART I | ||
| ITEM 1. | BUSINESS | 5 |
| ITEM 1A. | RISK FACTORS | 48 |
| ITEM 1B. | UNRESOLVED STAFF COMMENTS | 108 |
| ITEM 1C. | CYBERSECURITY | 108 |
| ITEM 2. | PROPERTIES | 109 |
| ITEM 3. | LEGAL PROCEEDINGS | 109 |
| ITEM 4. | MINE SAFETY DISCLOSURES | 109 |
| PART II | ||
| ITEM 5. | MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. | 110 |
| ITEM 6. | RESERVED | 110 |
| ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 111 |
| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 125 |
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 126 |
| ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 160 |
| ITEM 9A. | CONTROLS AND PROCEDURES | 160 |
| ITEM 9B. | OTHER INFORMATION | 161 |
| ITEM 9C. | DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS | 161 |
| PART III | ||
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 162 |
| ITEM 11. | EXECUTIVE COMPENSATION | 162 |
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS | 162 |
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE | 162 |
| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES | 162 |
| PART IV | ||
| ITEM 15. | EXHIBIT AND FINANCIAL STATEMENT SCHEDULES | 163 |
| | | |
| EXHIBIT INDEX | 163 | |
| SIGNATURES | 167 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.